Thyroid Carcinoma, Anaplastic: all 87 studies

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 2
• Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingNCT07863765Phase 2
• Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid CancerRecruitingNCT07777536Phase 2
• Drug Repurposing in Thyroid Carcinoma: a Feasibility TrialRecruitingNCT07485569Phase 1
• Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
• Taiwanese Anaplastic Thyroid Cancer RegistryNot yet recruitingNCT07138261
• Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerRecruitingNCT07068542Not applicable
• XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingNCT06902376Phase 1
• [177Lu]Lu-AKIR001 First-in-human StudyRecruitingNCT06639191Early Phase 1
• Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
• Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapyRecruitingNCT06362694Phase 2
• Sacituzumab govitEcan in THYroid CancersRecruitingNCT06235216Phase 2
• NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)RecruitingNCT06079333Phase 2
• Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study ExperiencesNot yet recruitingNCT05819593
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 2
• Study of Clinical Outcomes of Thyroid CancerRecruitingNCT04031339
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/2Results posted
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerCompletedNCT04552769Phase 2Results posted
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
• Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid CancerCompletedNCT03211117Phase 2Results posted
• CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerTerminatedNCT03002623Phase 2Results posted
• Pembrolizumab in Anaplastic/Undifferentiated Thyroid CancerCompletedNCT02688608Phase 2Results posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedNCT02244463Phase 1/2Results posted
• Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid CancerCompletedNCT02152137Phase 2Results posted
• Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
• A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)CompletedNCT01240590Phase 1/2Results posted
• Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCompletedNCT01236547Phase 2Results posted
• Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid CancerCompletedNCT00654238Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
• A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With PaclitaxelTerminatedNCT00603941Phase 1/2Results posted
• Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid CancerTerminatedNCT00507429Phase 2/3Results posted
• Iodine I 131 in Treating Patients With Thyroid CancerTerminatedNCT00416949Not applicableResults posted
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid CancerTerminatedNCT00126568Phase 2Results posted
• Trial Evaluating Gleevec in Patients With Anaplastic Thyroid CarcinomaTerminatedNCT00115739Phase 2Results posted
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyCompletedNCT00095836Phase 2Results posted
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid TumorsSuspendedNCT07181720Phase 1
• IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 2
• European Multicenter Study on Surgical Management of Advanced Thyroid CancerStatus unknownNCT05796960
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2
• A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 1
• Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerSuspendedNCT05453799Phase 2
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationActive, not recruitingNCT05102292Phase 1/2
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
• Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWithdrawnNCT04739566Phase 2
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)Status unknownNCT04574817Phase 2
• Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid CancerActive, not recruitingNCT04420754Phase 1
• JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 1
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 2
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedNCT03975231Phase 1
• The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
• Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid CancerCompletedNCT03565536Phase 2
• Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3CompletedNCT03488134
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
• Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingNCT03181100Phase 2
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1
• Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerActive, not recruitingNCT03085056Early Phase 1
• Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer PatientsCompletedNCT02862470
• Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid CancerCompletedNCT02726503Phase 2
• A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid CancersWithdrawnNCT02516774Phase 1
• Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid CancerWithdrawnNCT02289144Phase 2
• Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.TerminatedNCT02012231Phase 1
• interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)Status unknownNCT01774279
• Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerWithdrawnNCT01701349Phase 3
• Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid CancerCompletedNCT01164176Phase 2
• Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid CancerStatus unknownNCT01118065Phase 2
• S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid TumorsWithdrawnNCT00937417Phase 1
• Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid CancerTerminatedNCT00804830Phase 2
• Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid CancerStatus unknownNCT00786552Phase 2
• Review of Multimodality Management of Anaplastic Thyroid CancerCompletedNCT00280852
• NGR-TNF in Treating Patients With Advanced Solid TumorsCompletedNCT00098943Phase 1
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerCompletedNCT00095693Phase 2
• Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid CancerTerminatedNCT00077103Phase 1/2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver MetastasesCompletedNCT00062348Phase 1
• Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid CancerCompletedNCT00060242Phase 2
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
• Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
• SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckCompletedNCT00005647Phase 1
• Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid CancerCompletedNCT00004089Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2

← Thyroid Carcinoma, Anaplastic overview